Understanding the sleep-wake cycle: Sleep, insomnia, and the orexin system

Journal of Clinical Psychiatry

Volumn 74, Issue SUPPL.1, 2013, Pages 3-20

  Krystal, Andrew D ^a   Benca, Ruth M ^b   Kilduff, Thomas S ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; GALANIN; HISTAMINE; HISTAMINE H1 RECEPTOR; MELATONIN; MUSCARINIC M1 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; NORADRENALIN; OREXIN; PLACEBO; QUAZEPAM; RAMELTEON; SEROTONIN; TEMAZEPAM; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM;

ANXIETY; BEDTIME DOSAGE; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE THERAPY; COMORBIDITY; CONFERENCE PAPER; DAYTIME SOMNOLENCE; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; FATIGUE; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; SORE THROAT; SUICIDE; TASTE DISORDER;

EID: 84884776585     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13011su1c     Document Type: Conference Paper

References (98)

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Chicago, IL: American Academy of Sleep Medicine; 2001. http://www.esst.org/adds/ICSD.pdf. Accessed June 4, 2013.
2. Ishak WW, Bagot K, Thomas S, et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci. 2012;9(10):13-26. PubMed
3. Roth T. Prevalence, associated risks, and treatment patterns of insomnia. J Clin Psychiatry. 2005;66(suppl 9):10-13. PubMed
4. Borbely AA. A two process model of sleep regulation. Hum Neurobiol. 1982;1(3):195-204. PubMed
5. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257-1263. doi:10.1038/nature04284 PubMed
6. Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol. 2005;493(1):92-98. doi:10.102/cne.2070 PubMed
7. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996- 10015. PubMed
8. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci. 2006;27(7):368-374. doi:10.1016/j.tips.206.05.06 PubMed
9. Zeitzer JM, Buckmaster CL, Parker KJ, et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci. 2003;23(8):3555-3560. PubMed
10. Zhang S, Zeitzer JM, Yoshida Y, et al. Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep. 2004;27(4):619-627. PubMed
11. Morgan PT, Pace-Schott EF, Mason GF, et al. Cortical GABA levels in primary insomnia. Sleep. 2012;35(6):807-814. PubMed
12. Plante DT, Jensen JE, Schoerning L, et al. Reduced ?-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder? Neuropsychopharmacology. 2012;37(6):1548-1557. doi:10.1038/np.2012.4 PubMed
13. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150-155. doi:10.1038/nm154 PubMed
14. Wu MF, John J, Maidment N, et al. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol. 2002;283(5):R1079-R1086. PubMed
15. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005;46(5):787-798. doi:10.1016/j.neuron.205.04.035 PubMed
16. Blouin AM, Fried I, Wilson CL, et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun. 2013;4:1547. doi:10.1038/ncoms2461 PubMed
17. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504. PubMed
18. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep. 2006;29(11):1415-1419. PubMed
19. Espie CA. "Stepped care": a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep. 2009;32(12):1549-1558. PubMed
20. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. 2001;285(14):1856-1864. doi:10.101/jama.285.14.1856 PubMed
21. Espie CA, Inglis SJ, Tessier S, et al. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther. 2001;39(1):45-60. doi:10.1016/S05-7967(9)0157-6 PubMed
22. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep. 2006;29(11):1398-1414. PubMed
23. Stahl MS. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
24. Krystal AD, Richelson E, Roth T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev. 2013;17(4):263-272. doi:10.1016/j.smrv.2012.08.01 PubMed
25. Kalpaklioglu F, Baccioglu A. Efficacy and safety of H1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem. 2012;11(3):230-237. PubMed
26. Hajak G, Rodenbeck A, Staedt J, et al. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116-122. doi:10.1/j.160-079X.195.tb0179.x PubMed
27. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS ONE. 2013;8(5):e63773. doi:10.1371/journal.pone.06373 PubMed
28. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012;13(6):895-905. doi:10.1517/1465656.2012.67076 PubMed
29. Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Sleep Med Rev. 2011;15(2):99-106. doi:10.1016/j.smrv.2010.04.01 PubMed
30. Gooneratne NS. Complementary and alternative medicine for sleep disturbances in older adults. Clin Geriatr Med. 2008;24(1):121-138, viii. doi:10.1016/j.cger.207.08.02 PubMed
31. Taibi DM, Landis CA, Petry H, et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11(3):209-230. doi:10.1016/j.smrv.207.03.02 PubMed
32. Silenor (doxepin) [package insert]. San Diego, CA: Somaxon Pharmaceuticals, Inc; 2010.
33. Estazolam [package insert]. Sellersville, PA: Teva Pharmaceuticals USA; 2008.
34. Lunesta (eszopiclone) [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 2012.
35. Flurazepam [package insert]. Libertyville, IL: A-S Medical Solutions; 2010.
36. Doral (quazepam) [package insert]. Hayward, CA: Questor Pharmaceuticals, Inc; 2013.
37. Rozerem (ramelteon) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2010.
38. Restoril (temazepam) [package insert]. Hazelwood, MO: Mallinckrodt Inc; 2011.
39. Halcion (triazolam) [package insert]. New York, NY: Pharmacia & Upjohn Inc; 2013.
40. Sonata (zaleplon) [package insert]. Bristol, TN: King Pharmaceuticals, Inc; 2011.
41. Ambien (zolpidem) [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2013.
42. Zolpidem extended release [package insert]. Irvine, CA: Anchn Pharmaceuticals, Inc; 2011.
43. Intermezzo (zolpidem sublingual) [package insert]. Stamford, CT: Purdue Pharma LP; 2014.
44. Drugs for insomnia. Treat Guidel Med Lett. 2009;7(79):23-26. PubMed
45. Krystal AD, McCall WV, Fava M, et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim Care Companion CNS Disord. 2012;14(4):doi:10.4088/ pcc.11m01296. PubMed
46. Roth T, Krystal A, Steinberg FJ, et al. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013;36(2):189-196. PubMed
47. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3(5):495-504. PubMed
48. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7(1):17-24. doi:10.1016/j.slep.205.09.04 PubMed
49. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561. PubMed
50. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69(10):1557-1564. doi:10.408/JCP.v69n105 PubMed
51. Patel D, Goldman-Levine JD. STEPS New Drug Reviews: Doxepin (Silenor) for Insomnia. http://www.aafp.org/afp/2011/0815/p453.html. August 15, 2011. Accessed June 11, 2013.
52. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476. doi:10.408/JCP.v6n0409 PubMed
53. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003). 2012;52(6):e210-e219. doi:10.131/JAPhA.2012.12051 PubMed
54. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):3-7. PubMed
55. McCall C, McCall WV. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Curr Psychiatry Rep. 2012;14(5):494-502. doi:10.107/s1920-012-0302-y PubMed
56. Wilson S, Nutt D. Management of insomnia: treatments and mechanisms. Br J Psychiatry. 2007;191(3):195-197. doi:10.192/bjp.bp.107.036301 PubMed
57. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622. PubMed
58. Quintero JE, Dooley DJ, Pomerleau F, et al. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ a2d-1 subunit. J Pharmacol Exp Ther. 2011;338(1):240-245. doi:10.124/jpet.10.178384 PubMed
59. Purves D, Augustine GJ, Fitzpatrick D, et al. Neuroscience. 2nd ed. Sunderland, MA: Sinauer Associates; 2001.
60. Wong CG, Bottiglieri T, Snead OC 3rd. GABA, gamma-hydroxybutyric acid, and neurological disease. Ann Neurol. 2003;54(suppl 6):S3-S12. doi:10.102/ana.10696 PubMed
61. Neubauer DN. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med. 2007;3(suppl):S11-S15. PubMed
62. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179(5):390-396. doi:10.192/bjp.179.5.390 PubMed
63. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem. 2002;2(8):795-816. doi:10.2174/156802602393507 PubMed
64. Ong J, Kerr DI. Recent advances in GABAB receptors: from pharmacology to molecular biology. Acta Pharmacol Sin. 2000;21(2):111-123. PubMed
65. Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231-239. doi:10.1016/S0306-452(02)034-9 PubMed
66. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233. PubMed
67. Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of nonbenzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345(6):e8343. doi:10.136/bmj.e8343 PubMed
68. Krystal AD, Erman M, Zammit GK, et al, for the ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79-90. PubMed
69. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799. PubMed
70. Vienne J, Lecciso G, Constantinescu I, et al. Differential effects of sodium oxybate and baclofen on EEG, sleep, neurobehavioral performance, and memory. Sleep. 2012;35(8):1071-1083. PubMed
71. Pardi D, Black J. gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20(12):993-1018. doi:10.2165/023210-20620120-04 PubMed
72. O'Connell T, Kaye L, Plosay JJ 3rd. Gamma-hydroxybutyrate (GHB): a newer drug of abuse. Am Fam Physician. 2000;62(11):2478-2483. PubMed
73. Finnimore AJ, Roebuck M, Sajkov D, et al. The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J. 1995;8(2):230-234. doi:10.183/09031936.95.08020230 PubMed
74. Orr WC, Goodrich S, Wright S, et al. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil. 2012;24(6):553-559, e253. doi:10.1/j.1365-2982. 2012.0190.x PubMed
75. Walsh JK. Enhancement of slow wave sleep: implications for insomnia. J Clin Sleep Med. 2009;5(suppl):S27-S32. PubMed
76. Mathias S, Wetter TC, Steiger A, et al. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging. 2001;22(2):247-253. doi:10.1016/S0197-4580(0)0232-3 PubMed
77. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322-327. doi:10.1073/pnas.95.1.32 PubMed
78. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-585. doi:10.1016/S092-8674(0) 80949-6 PubMed
79. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-474. doi:10.1016/S0896- 6273(0)058-1 PubMed
80. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991-997. doi:10.1038/79690 PubMed
81. National Institute of Neurological Disorders and Stroke. Narcolepsy Fact Sheet. http://www.ninds.nih.gov/disorders/narcolepsy/detail-narcolepsy.htm. Updated December 28, 2011. Accessed June 4, 2013.
82. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-376. doi:10.1016/S092-8674(0)81965-0 PubMed
83. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437-451. doi:10.1016/S092-8674(0)81973-X PubMed
84. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-1562. doi:10.101/archneur.59.10.153 PubMed
85. Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61(2):162-176. doi:10.124/pr.109.01321 PubMed
86. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51(1):243-266. doi:10.146/anurev-pharmtox-010510-10528 PubMed
87. Actelion. Actelion and GSK discontinue clinical development of almorexant. http://www1.actelion.com/en/our-company/news-and-events/index. page?newsId=1483135. Published January 28, 2011. Accessed June 5, 2013.
88. Whitman DB, Cox CD, Breslin MJ, et al. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4- diazepane scaffold that promotes sleep in rats. Chem Med Chem. 2009;4(7):1069-1074. doi:10.102/cmdc.209069 PubMed
89. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265-2274. doi:10.1212/WNL.0b013e3182768e PubMed
90. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259-267. PubMed
91. Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia [published online ahead of print June 3, 2013]. Br J Pharmacol. doi:10.1111/bph.12261. doi:10.1/bph.1261 PubMed
92. Bettica P, Nucci G, Pyke C, et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol. 2012;26(8):1058-1070. doi:10.17/026981408954 PubMed
93. Bettica P, Squassante L, Zamuner S, et al. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep. 2012;35(8):1097-1104. PubMed
94. Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330(1):142-151. doi:10.124/jpet.109.15209 PubMed
95. Morairty SR, Revel FG, Malherbe P, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE. 2012;7(7):e39131. doi:10.1371/journal.pone.039131 PubMed
96. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715-730. doi:10.1016/S0896-6273(03)030-1 PubMed
97. Black SW, Morairty SR, Fisher SP, et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep. 2013;36(3):325-336. PubMed
98. Poli F, Plazzi G, Di Dalmazi G, et al. Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep. 2009;32(11):1491- 1497. PubMed